mirtazapine + paroxetine + trazodone

This is a non-standard, off-label combination of three antidepressant medications—mirtazapine, paroxetine, and trazodone—sometimes used in treatment-resistant depression. Each drug has a distinct mechanism of action that may provide complementary effects when combined. Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA) that antagonizes central presynaptic alpha-2 adrenergic receptors as well as serotonin 5HT2A/5HT2C/5HT3 receptors and histamine H1 receptors. Paroxetine is a selective serotonin reuptake inhibitor (SSRI) that primarily inhibits the serotonin transporter (SERT), increasing synaptic serotonin levels. Trazodone acts as a serotonin antagonist and reuptake inhibitor (SARI), blocking 5HT2A/5HT2C receptors, weakly inhibiting SERT, antagonizing alpha-1 adrenergic and histamine H1 receptors. The rationale for this triple combination is to maximize serotonergic neurotransmission through multiple mechanisms while also targeting noradrenergic pathways and providing additional sedative effects via histamine receptor antagonism. This approach may be considered in cases where dual therapy fails to achieve remission or when residual symptoms such as insomnia persist[1][3]. However, combining these agents increases the risk of adverse effects—including additive sedation, anticholinergic burden, orthostatic hypotension—and particularly raises the risk for serotonin syndrome[10][7]. The use of three antidepressants simultaneously remains controversial due to limited evidence on efficacy versus increased side-effect burden; it should only be considered under close medical supervision for select patients with treatment-resistant depression[3][2].